Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol (2000) 5.13

Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol (2001) 2.66

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol (2005) 2.40

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol (2001) 2.30

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol (2001) 2.16

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol (2003) 2.14

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13

Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J Virol (2003) 1.92

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58

Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J Virol (2003) 1.56

Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol (1999) 1.55

Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol (2007) 1.44

Non-human primate models for AIDS vaccine research. Curr Drug Targets Infect Disord (2005) 1.40

Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J Virol (2010) 1.38

Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo. J Virol (2000) 1.33

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol (2002) 1.32

Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc Natl Acad Sci U S A (2012) 1.28

Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. J Virol (2001) 1.28

Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J Virol (2002) 1.25

Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol (2005) 1.17

Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus. J Virol (1999) 1.14

Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. J Virol (2005) 1.09

Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype. J Virol (2011) 1.07

Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques. J Virol (2001) 1.02

Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques. J Virol (2013) 0.91

The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques. J Virol (2013) 0.86

Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates. J Virol (2002) 0.83

Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. J Virol (2016) 0.78

A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates. J Virol Methods (2010) 0.77

Small intestine CD4+ cell reduction and enteropathy in simian/human immunodeficiency virus KS661-infected rhesus macaques in the presence of low viral load. J Gen Virol (2009) 0.76

Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13

Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science (1984) 15.82

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med (1995) 8.23

A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol (1995) 7.30

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis (1996) 5.14

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol (1996) 5.06

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol (1995) 5.01

An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol (1992) 4.85

Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1990) 4.46

Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol (1995) 4.33

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med (1995) 4.28

Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol (1988) 4.25

Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr (1992) 3.94

An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol (1996) 3.51

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35

Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol (1994) 3.32

Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci U S A (1995) 3.23

Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol (1997) 3.10

Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol (1996) 3.04

Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J Virol (1996) 2.86

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis (1996) 2.84

The antibody response in HIV-1 infection. AIDS (1997) 2.79

Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol (1996) 2.45

Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J Virol (1997) 2.28

Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol (1995) 2.24

Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol (1995) 2.22

The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J (1996) 2.21

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci U S A (1994) 2.09

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA (1994) 2.05

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses (1994) 1.83

Coreceptors: implications for HIV pathogenesis and therapy. Science (1997) 1.81

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses (1995) 1.72

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67

V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. J Clin Invest (1993) 1.67

Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. J Infect Dis (1997) 1.57

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol (1996) 1.57

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses (1995) 1.56

Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol (1995) 1.37

Measuring vaccine-induced HIV neutralization: report of a workshop. AIDS Res Hum Retroviruses (1994) 1.36

SIV/HIV recombinants and their use in studying biological properties. AIDS Res Hum Retroviruses (1992) 1.35

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet (1993) 1.15

Serological responses to candidate AIDS vaccines. AIDS Res Hum Retroviruses (1994) 0.90

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54

The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90

The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell (1985) 11.28

The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell (1986) 10.76

Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A (1991) 10.05

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92

Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27

Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science (1984) 9.14

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol (1999) 9.11

Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A (1988) 7.74

Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66

The isolation and characterization of the human suppressor inducer T cell subset. J Immunol (1985) 6.69

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A (1989) 6.58

Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science (1985) 6.02

A novel murine oncornavirus with dual eco- and xenotropic properties. Proc Natl Acad Sci U S A (1975) 5.91

Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A (1989) 5.72

Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci U S A (1986) 5.55

Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc Natl Acad Sci U S A (1988) 5.47

Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet (1998) 5.46

Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III. Nature (1986) 5.24

The isolation and characterization of the human helper inducer T cell subset. J Immunol (1985) 5.21

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol (1996) 5.06

A proposed nomenclature for the virion proteins of oncogenic RNA viruses. Virology (1974) 5.01

Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A (1986) 4.68

Effects of mutations within the 3' orf open reading frame region of human T-cell lymphotropic virus type III (HTLV-III/LAV) on replication and cytopathogenicity. J Virol (1986) 4.48

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science (1990) 4.43

Identification of HIV-1 vpr product and function. J Acquir Immune Defic Syndr (1990) 4.35

Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol (1990) 4.35

A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J Exp Med (1989) 4.16

Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol (1988) 4.13

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11

Identification of a protein encoded by the vpu gene of HIV-1. Nature (1988) 4.05

Ia antigen expression on human epidermal Langerhans cells. Nature (1977) 4.05

Association of viral reverse transcriptase with an enzyme degrading the RNA moiety of RNA-DNA hybrids. Nat New Biol (1971) 3.95

Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr (1992) 3.94

Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature (1987) 3.77

Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science (1985) 3.74

Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol (1994) 3.71

Assembly of type C oncornaviruses: a model. Science (1978) 3.53

An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol (1996) 3.51

Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A (1987) 3.47

Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell (1996) 3.44

Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol (2001) 3.40

Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J (1969) 3.37

Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med (1998) 3.35

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35

Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J Virol (1993) 3.27

Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene. Science (1984) 3.20

Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. J Gen Virol (1987) 3.18

Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol (1999) 3.17

Possible immunological factors in human malignant melanoma in Uganda. Lancet (1967) 3.16

Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (1989) 3.13

A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol (1995) 3.11

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A (1997) 3.02

Cis-acting sequences responsive to the rev gene product of the human immunodeficiency virus. J Acquir Immune Defic Syndr (1988) 2.97

Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures. Virology (1973) 2.94

Autoimmunization with irradiated tumour cells in human malignant melanoma. Br Med J (1970) 2.91

In vitro growth characteristics of simian T-lymphotropic virus type III. Proc Natl Acad Sci U S A (1985) 2.90

Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J Immunol (1991) 2.77

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med (1999) 2.77

Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69

Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes. J Immunol (1988) 2.68

The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67

Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol (2001) 2.66

Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc Natl Acad Sci U S A (1987) 2.66

Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65

Subcellular localization of the human immunodeficiency virus trans-acting art gene product. J Virol (1988) 2.64

Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type I X-region genes transduced by a Herpesvirus saimiri vector. Proc Natl Acad Sci U S A (1989) 2.64

Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A (1987) 2.53

Ribonucleic acid components of BAI strain A (myeloblastosis) avian tumor virus. Cancer Res (1967) 2.53

Nononcogenic deletion mutants of herpesvirus saimiri are defective for in vitro immortalization. J Virol (1986) 2.52

Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol (1997) 2.51

Construction of recombinant murine retroviruses that express the human T-cell leukemia virus type II and human T-cell lymphotropic virus type III trans activator genes. J Virol (1986) 2.50

Polypeptides of avian RNA tumor viruses. 1. Isolation and physical and chemical analysis. Virology (1970) 2.49

Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol (1997) 2.34

Experience with a three-hour electron microscopy biopsy service. J Clin Pathol (1974) 2.33

Cellular localization of simian immunodeficiency virus in lymphoid tissues. I. Immunohistochemistry and electron microscopy. Am J Pathol (1989) 2.33

Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J Virol (1997) 2.28

Location of cis-acting regulatory sequences in the human T-cell leukemia virus type I long terminal repeat. Proc Natl Acad Sci U S A (1985) 2.25

Immunological studies in nephrotic syndrome associated with extrarenal malignant disease. Lancet (1971) 2.22

Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol (1995) 2.22

A new type D retrovirus isolated from macaques with an immunodeficiency syndrome. Science (1984) 2.22

Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol (1992) 2.21

Acquired immunodeficiency syndrome in a colony of macaque monkeys. Proc Natl Acad Sci U S A (1983) 2.17